Lab
Trucore Laboratories, LLC
Trucore Laboratories, LLC was paid $4.68M by Medicaid between Nov 2020 and Dec 2024, across 53 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 62% of everything it billed.
33Billing provider infoTRUCORE LABORATORIES, LLC
CHARLOTTE, NC 28217
CHARLOTTE, NC 28217
33aNPI1730708215assigned 04/14/2020
33bProvider typeClinical Medical Laboratory
28Total paid$4.68M
24GClaims69,335
24DCodes billed53
24AFirst – last monthNov 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in North Carolina
Rank by total paid#22 of 128
Median peer was paid$268K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 47 | $3K | |
| 2021 | 3,448 | $393K | |
| 2022 | 16,631 | $1.95M | |
| 2023 | 10,230 | $853K | |
| 2024incomplete | 38,979 | $1.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 62% | 23,142 | 13,356 | $2.92M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13% | 9,555 | 8,749 | $588K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.3% | 11,346 | 1,280 | $248K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.0% | 977 | 936 | $143K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.6% | 2,241 | 1,917 | $124K |
| 87529 | 1.7% | 3,437 | 1,215 | $81K | |
| 87481 | 1.6% | 3,383 | 460 | $73K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,340 | 1,282 | $46K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,615 | 1,225 | $41K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,254 | 1,194 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,185 | 1,127 | $31K |
| 87625 | <1% | 1,268 | 1,178 | $28K |
41 more codes
| 87563 | <1% | 1,037 | $28K | |
| 87653 | <1% | 1,031 | $27K | |
| 83013 | <1% | 291 | $22K | |
| 88312 | <1% | 334 | $21K | |
| 87641 | <1% | 838 | $21K | |
| 86409 | <1% | 261 | $19K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 41 | $14K |
| 80434 | <1% | 169 | $13K | |
| 83009 | <1% | 200 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 57 | $11K |
| 87500 | <1% | 420 | $11K | |
| 87428 | <1% | 177 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 411 | $11K |
| 81507 | <1% | 15 | $9K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 173 | $9K |
| 80435 | <1% | 113 | $9K | |
| 86413 | <1% | 159 | $8K | |
| 87640 | <1% | 415 | $8K | |
| 87507 | <1% | 34 | $7K | |
| 87632 | <1% | 60 | $6K | |
| 80420 | <1% | 84 | $5K | |
| 86769 | <1% | 123 | $5K | |
| 87631 | <1% | 58 | $4K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 31 | $4K |
| 80410 | <1% | 74 | $4K | |
| 88323 | <1% | 46 | $4K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 38 | $4K |
| 88313 | <1% | 77 | $4K | |
| 83088 | <1% | 116 | $4K | |
| 88342 | <1% | 53 | $3K | |
| 82375 | <1% | 184 | $2K | |
| 88314 | <1% | 31 | $1K | |
| 86710 | <1% | 73 | $972.67 | |
| 80050 | General health panel | <1% | 122 | $857.30 |
| 82383 | <1% | 38 | $845.23 | |
| 83090 | <1% | 48 | $762.72 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 24 | $724.47 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 61 | $636.92 |
| 82382 | <1% | 38 | $611.12 | |
| 87501 | <1% | 13 | $387.45 | |
| 81513 | 0% | 1,024 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOXX, ENRICO (CEO)